Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cogent Biosciences is a biotechnology business based in the US. Cogent Biosciences shares (COGT) are listed on the NASDAQ and all prices are listed in US Dollars. Cogent Biosciences employs 121 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $14.84 |
|---|---|
| 52-week range | $3.79 - $18.07 |
| 50-day moving average | $11.75 |
| 200-day moving average | $11.08 |
| Wall St. target price | $22.14 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.21 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $14.84 from 2023-01-25
| 1 week (2023-01-20) | 10.66% |
|---|---|
| 1 month (2022-12-27) | 37.66% |
| 3 months (2022-10-27) | 9.93% |
| 6 months (2022-07-27) | 32.97% |
| 1 year (2022-01-23) | N/A |
|---|---|
| 2 years (2021-01-27) | 54.58% |
| 3 years (2020-01-27) | 1,414.44% |
| 5 years (2018-01-23) | N/A |
| Gross profit TTM | $-55,913,000 |
|---|---|
| Return on assets TTM | -29.65% |
| Return on equity TTM | -51.54% |
| Profit margin | 0% |
| Book value | $3.21 |
| Market capitalisation | $880.7 million |
TTM: trailing 12 months
We're not expecting Cogent Biosciences to pay a dividend over the next 12 months.
Cogent Biosciences's shares were split on a 1:4 basis on 9 November 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cogent Biosciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Cogent Biosciences shares which in turn could have impacted Cogent Biosciences's share price.
Over the last 12 months, Cogent Biosciences's shares have ranged in value from as little as $3.79 up to $18.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cogent Biosciences's is -0.5813. This would suggest that Cogent Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cogent Biosciences has bucked the trend.
Cogent Biosciences, Inc. , a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
We explore some of the best brokerage accounts for international stock trading. Here’s what you need to know.
